Ici-Hipet
HIPEC
Jing LiPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the HIPEC cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Center, Korea | Phase 3 | B |
Sodium Thiosulfate National Cancer Center, Korea | Phase 3 | B |
Raltitrexed Fudan University | Phase 1 | CC |
Same molecule, other indications
Ici-Hipet is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →